BPC-157

BPC-157 is a 15-amino-acid peptide derived from human gastric juice that promotes angiogenesis and tissue repair by activating the FAK-paxillin pathway. It is one of 14 peptides under FDA reclassification review and has over 100 preclinical studies but no completed human clinical trials.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids — sequence GEPPPGKPADDAGLV — derived from a protective protein sequence found in human gastric juice. The parent compound was first isolated and characterized by Predrag Sikirić and colleagues at the University of Zagreb, where it has been the subject of sustained academic research since the early 1990s. The 'BPC' designation refers to Body Protection Compound, reflecting the original hypothesis that gastric juice contains endogenous cytoprotective factors. Numbered 157 in the research sequence, it has proven to be the most biologically active stable fragment. Unlike many research peptides that exist in a single-laboratory scientific vacuum, BPC-157 has generated over 100 peer-reviewed preclinical publications across multiple independent research groups — giving it an unusually robust (if entirely animal-model) evidence base.

BPC-157 is gastric acid-stable — an unusual property for a peptide — which means it resists enzymatic degradation in the digestive tract, enabling oral bioavailability for gut-targeted applications while also being effective systemically via subcutaneous or intramuscular injection. This dual-route capability makes it unique among tissue-repair peptides, which typically require injection to be effective. The oral route is pharmacologically relevant specifically for gastrointestinal tract applications (mucosal repair, ulcer healing, gut motility disorders), while injection is preferred for musculoskeletal, tendon, and ligament healing.

The clinical applications most supported by preclinical evidence span four domains: musculoskeletal (tendon, ligament, muscle, and bone repair), gastrointestinal (mucosal cytoprotection, ulcer healing, inflammatory bowel disease models), neurological (TBI neuroprotection, peripheral nerve healing), and systemic anti-inflammatory modulation. BPC-157 is consistently among the top three most-discussed peptides in biohacking and sports recovery communities globally, frequently stacked with thymosin beta-4 (TB-500) in what users call the 'Wolverine stack' for comprehensive tissue repair.

As of 2026, BPC-157 is one of 14 peptides under FDA reclassification review as part of the RFK Jr. initiative examining peptides that were removed from compounding pharmacy availability without completed human clinical trials. No human clinical trial data has been published, though Phase I safety studies have been initiated. Most US research chemical suppliers halted sales in 2025–2026 pending regulatory clarity, making it simultaneously one of the most popular and least accessible peptides in the US market.

BPC-157 engages a convergent set of intracellular signaling pathways rather than a single receptor, which partly explains its unusually broad tissue-type efficacy. The best-characterized mechanism is activation of the FAK-paxillin pathway (focal adhesion kinase / paxillin complex), which governs cell migration, adhesion, and proliferation in fibroblasts, tenocytes, and endothelial cells. Chang et al. (J Appl Physiol, 2011) demonstrated that BPC-157 promotes tendon outgrowth in explant cultures specifically through FAK-paxillin signaling, with inhibition of this pathway abolishing the pro-healing effect. This mechanism is shared across multiple cell types: the same FAK activation underpins BPC-157's effects in gut epithelial repair, muscle satellite cell mobilization, and vascular endothelial proliferation.

Angiogenesis — the formation of new blood vessels — is a second major mechanism, mediated through upregulation of VEGF (vascular endothelial growth factor) and eNOS (endothelial nitric oxide synthase). BPC-157 increases nitric oxide production via eNOS in endothelial cells, which triggers vasodilation and proangiogenic signaling. Sikiric et al. have extensively characterized this NO-mediated mechanism as the explanation for BPC-157's protective effects in ischemia models: by restoring microvascular perfusion to injured tissue, BPC-157 accelerates healing even in poorly vascularized structures like tendons, which are notoriously difficult to repair due to their naturally low blood supply.

In the gastrointestinal tract, BPC-157 acts through multiple cytoprotective mechanisms: it counteracts NSAID-induced suppression of prostaglandin synthesis, reduces acid-induced mucosal apoptosis, promotes mucosal cell migration and restitution, and inhibits the inflammatory cascade triggered by ethanol or indomethacin. Interestingly, BPC-157 has also demonstrated dopaminergic and serotonergic modulatory activity in CNS models — decreasing dopamine turnover in limbic structures and normalizing serotonergic activity — suggesting mechanisms relevant to mood, neuroprotection, and gut-brain axis modulation that extend beyond simple tissue repair.

The BPC-157 preclinical literature is one of the most extensive for any research peptide, with over 100 published studies predominantly from the Sikiric laboratory at the University of Zagreb, supplemented by independent groups in Asia and North America. The breadth of models studied is unusual: tendon (Achilles, patellar, rotator cuff), ligament (MCL, ACL), muscle (crush injury, ischemia-reperfusion), bone (calvarial defects, tibial fractures), gut (ulcer, IBD models, fistula repair, anastomosis healing), peripheral nerve, TBI, and cardiac ischemia.

In musculoskeletal research, the landmark tendon study (Staresinic et al., J Orthop Res, 2003) demonstrated that BPC-157 accelerated healing of fully transected rat Achilles tendons, with treated animals achieving 72% of contralateral tendon strength at 14 days versus ~40% for controls. Histologically, treated tendons showed earlier vascular ingrowth, higher type I collagen deposition, and improved collagen fiber organization. Repeating this model with the rotator cuff (Chang et al., 2011) confirmed FAK-paxillin-mediated tenocyte outgrowth as the mechanism. Muscle crush injury models consistently show reduced fibrosis and faster functional recovery with BPC-157 versus saline controls.

Gastrointestinal evidence is particularly strong because it mirrors the proposed physiological role of BPC-157 as a gastric cytoprotective factor. Sikiric et al. (Eur J Pharmacol, 1993, 1997) established BPC-157's ability to prevent and heal NSAID-induced gastric ulcers, ethanol-induced mucosal hemorrhage, and surgical anastomotic leaks in rat models — effects achieved at doses as low as 10 ng/kg, suggesting high potency. A 2016 study in IBD models (Sikiric et al., World J Gastroenterol) demonstrated reduced TNF-α, IL-6, and COX-2 expression in intestinal tissue of BPC-157-treated rats with induced colitis.

Neurological models represent a newer area of investigation. BPC-157 demonstrated neuroprotective effects in traumatic brain injury models (reduced lesion volume, improved motor and cognitive testing), peripheral nerve crush and transection models (accelerated remyelination and functional recovery), and spinal cord injury (partial motor recovery versus controls). These findings have attracted significant interest given the lack of effective pharmacological interventions for CNS trauma.

The critical limitation is the complete absence of human clinical trial data. As of 2026, no Phase I–III trials have been published, meaning all efficacy and safety inferences from BPC-157 research involve extrapolating from rodent models to human biology. The translation gap is real: many peptides with robust rodent efficacy have failed in human trials. However, BPC-157's gastric origin and the stability data suggesting oral bioavailability are scientifically compelling rationales for eventual clinical investigation. A Phase I safety trial has been initiated but not yet reported.[1][2][3][4][5][6]

Peptides commonly paired with BPC-157 for synergistic effects.